We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.48 | 0.30% | 162.00 | 163.05 | 159.69 | 161.07 | 5,483,869 | 23:47:17 |
From May 2019 to May 2024
By Colin Kellaher
AbbVie Inc. on Tuesday said it is seeking approval from the U.S. Food and Drug Administration for expanded use of Rinvoq for the treatment of adults with active ankylosing spondylitis.
AbbVie also said it has also filed for European Medicines Agency approval of Rinvoq for adults with active ankylosing spondylitis who have responded inadequately to conventional therapy.
The North Chicago, Ill., biopharmaceutical company said the applications are supported by data from a Phase 2/3 study in which Rinvoq showed significant improvements in signs and symptoms of the chronic, progressive, inflammatory musculoskeletal disease.
Last year, Rinvoq received U.S. and European approval for adults with moderately to severely active rheumatoid arthritis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 25, 2020 10:09 ET (14:09 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
